CATX · Perspective Therapeutics, Inc. · Insider Trading

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0448 to $3.1775, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.13, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.025 to $3.235, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to Perspective Therapeutics, Inc. ("CATX"), any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.08 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

These sales were previously reported in Form 4s filed by Lantheus Holdings, Inc. on September 2, 2026 and September 3, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

Effective June 14, 2024, Perspective Therapeutics, Inc. ("CATX") effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.095 to $3.165, inclusive. The reporting person undertakes to provide to CATX, any security holder of CATX or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 4, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026, and represents the Reporting Person's annual equity award for 2026.

Option vests in full on March 2, 2027, subject to the Reporting Person's continued service on the vesting date.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0235 to $2.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on September 4, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.

Options vest and become exercisable over three years in 36 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each such vesting date.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.12 to $2.1697, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.19 to $2.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

Previous Form 4s filed on behalf of the Reporting Person under-reported the Reporting Person's holdings by 1,100 shares of Common Stock. The amount reported in this Form 4 reflects the correct amount.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.1900 to $2.2450, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price in the transaction described in this footnote.

The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Compensation Committee of the Issuer's Board of Directors on February 13, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025, and represents the Reporting Person's annual equity award for 2025.

Option vests in full on March 3, 2026, subject to the Reporting Person's continued service on the vesting date.

The option grant was approved by the Issuer's Board of Directors on February 12, 2025, with a grant date of March 3, 2025 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2025.

Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

The options vest over a four-year period, with one-fourth (1/4) vesting and becoming exercisable on January 6, 2026, and the remaining options vesting and becoming exercisable ratably over the following 36 months, subject to the continuous service of the Reporting Person as of each vesting date.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7596 to $3.7700, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.645 to $3.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (07/17/2024), subject to a continued service relationship.

Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the monthly anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.

This option shall fully vest on the first anniversary after the Grant Date (06/20/2024), subject to a continued service relationship.